NCT02164578View on ClinicalTrials.gov

Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk

PHASE3CompletedINTERVENTIONAL

Enrollment

179

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 12, 2018

Study Completion Date

April 30, 2020

Conditions

Type 2 Diabetic Patients

Interventions

DRUG

Rivaroxaban

DRUG

Aspirin

Trial Locations (5)

13125

Universitätsmedizin Berlin / Charité Campus Buch, Berlin

01067

Krankenhaus Dresden-Friedrichstadt, Dresden

01279

Gemeinschaftspraxis Dr. Schaper/ Dr. Faulmann, Dresden

01307

GWT-TUD GmbH / Studienzentrum Hanefeld, Dresden

01796

Cardiologicum Prina, Pirna

All Listed Sponsors

lead

GWT-TUD GmbH

OTHER

NCT02164578 - Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk | Biotech Hunter | Biotech Hunter